Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2019

01-06-2019 | Lung Cancer | editorial

Saving lives with lung cancer screening

Authors: Prim. Univ.-Prof. Dr. Wolfgang Hilbe, PD Dr. med. univ. Andreas Pircher

Published in: memo - Magazine of European Medical Oncology | Issue 2/2019

Login to get access

Excerpt

Lung cancer is the number one reason for cancer-related death in Austria and many other countries, especially due the fact that the majority of patients are diagnosed at an advanced stage of the disease. Two large trials (NLST and NELSON) proved the efficacy of low-dose CT (LD-CT) for lung cancer screening [1, 2]. Lung cancer deaths were decreased and early diagnosis facilitated curative treatment options. Thus, the risk to die from lung cancer was reduced by 26% in the NELSON trial. …
Literature
1.
National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef
2.
De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. PL02.05 effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J Thorac Oncol. 2018;13(10):185.CrossRef
3.
4.
5.
6.
7.
Metadata
Title
Saving lives with lung cancer screening
Authors
Prim. Univ.-Prof. Dr. Wolfgang Hilbe
PD Dr. med. univ. Andreas Pircher
Publication date
01-06-2019
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0496-3

Other articles of this Issue 2/2019

memo - Magazine of European Medical Oncology 2/2019 Go to the issue

short review

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance

case report

Solitary scalp metastatic lesion as a sign of breast cancer recurrence—a case report

educational

Educational no.5: next-generation gene panel sequencing

obituary

Obituary for Professor Michael Steurer

short review

Resistance to anti-hormonal therapy in prostate cancer

short review

Lung cancer screening from the oncologist’s perspective
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits